Downstaging locally advanced hepatocellular carcinoma with selective internal radiation therapy.

Author:

Hoang Marjorie1,Chow Pierce K. H.2

Affiliation:

1. Duke-NUS Medical School, Singapore, Singapore;

2. Department of Hepatopancreatobiliary and Transplantation Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore;

Abstract

536 Background: Locally advanced HCC (beyond BCLC A, including PVT but without extra-hepatic metastases) that are unresectable because of inadequate future liver remnant may be downstaged by selective internal radiation therapy (SIRT) with Yttrium-90 to subsequently receive interval surgical resection. We hypothesized that HCC that required downstaging before resection will have some disparity in overall survival (OS) and recurrence-free survival (RFS) compared to HCCs that were resected upfront. Methods: We reviewed all patients who underwent surgical resection for HCC between 1st January 2000 and 31st December 2019 and identified those that had locally advanced HCC and were downstaged with Y90-SIRT and referred for consideration of surgical resection. OS and RFS of patients resected upfront for early and locally advanced HCC and those resected after downstaging were obtained using the Kaplan Meier method and compared using Log-rank (Mantel-Cox) test after propensity score matching. Results: 1141 patients had surgical resection for HCC within the study period. 245 patients were excluded for other primary cancers or metastatic disease at diagnosis. 875 were resected upfront (473 early, 402 locally advanced) and 23 locally advanced HCC were downstaged with SIRT before resection. Locally advanced HCC patients downstaged with Y90 before resection have significantly better OS and RFS than locally advanced HCC with upfront resection (5-year OS of 69.0% versus 47.5% p = 0.048; 5-year RFS of 53.5% vs 27.0%, p = 0.047) and similar OS and RFS with resected early HCC (5-year OS of 69.0% versus 62.6% p=0.475; 5-year RFS of 53.5% vs 39.0%, p = 0.736). Conclusions: In addition to downstaging HCC to resection, Y90-SIRT also produces a change in tumour biology that favours better prognosis. A randomised controlled trial to the role of SIRT as neoadjuvant therapy in locally advanced HCC is justified and can potentially change practice.

Funder

None.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3